May 22, 2023 07:22 AM EDTUpdated 07:42 AM

Alnylam updates its pitch for expanded Onpattro label with 18-month PhIII data

Katherine Lewin

News Reporter

Alnylam Pharmaceuticals is so pleased with 18-month data from its Phase III trial investigating Onpattro as a treatment of ATTR cardiomyopathy that it

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alnylam updates its pitch for expanded Onpattro label with 18-month PhIII data

Katherine Lewin

News Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Al­ny­lam up­dates its pitch for ex­pand­ed On­pat­tro la­bel with 18-month PhI­II da­ta

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Alnylam updates its pitch for expanded Onpattro label with 18-month PhIII data